Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study

Osteoporosis International

Volumn 20, Issue 5, 2009, Pages 811-817

  McCloskey, E V ^a,c   Johansson, H ^a   Oden, A ^a   Vasireddy, S ^a   Kayan, K ^a   Pande, K ^a   Jalava, T ^b   Kanis, J A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Bayer Schering Pharma Oy   (Finland)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; BMD; Clodronate; Efficacy; Fracture probability; Fractures; Osteoporosis; Risk factors

Indexed keywords

CLODRONIC ACID; PLACEBO;

AGED; ALGORITHM; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HIP JOINT; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PROBABILITY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 63949087159     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0786-9     Document Type: Article

References (38)

1. E McCloskey 2004 Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study J Bone Miner Res 19 5 728 736
2. PD Delmas 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE Study Osteoporos Int 15 10 792 798
3. ST Harris 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 14 1344 1352
4. DM Black 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 9041 1535 1541
5. SR Cummings 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 24 2077 2082
6. J Reginster 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 83 91
7. MR McClung 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 5 333 340
8. ES Siris 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment JAMA 286 22 2815 2822
9. SA Wainwright 2005 Hip fracture in women without osteoporosis J Clin Endocrinol Metab 90 5 2787 2793
10. DM Black 2001 An assessment tool for predicting fracture risk in postmenopausal women Osteoporos Int 12 7 519 528
11. P Dargent-Molina 1996 Fall-related factors and risk of hip fracture: the EPIDOS Prospective Study Lancet 348 9021 145 149
12. PD Miller 2004 An approach to identifying osteopenic women at increased short-term risk of fracture Arch Intern Med 164 10 1113 1120
13. JA Kanis 2007 The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos Int 18 8 1033 1046
14. EV McCloskey 2007 Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study J Bone Miner Res 22 1 135 141
15. JA Kanis 2001 The burden of osteoporotic fractures: a method for setting intervention thresholds Osteoporos Int 12 5 417 427
16. Breslow NE, Day NE (1987) Statistical methods in cancer research, vol II. IARC Scientific Publications No 32, Lyon, pp 131-135
17. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843, pp 1-129 (1994)
18. JA Kanis 1997 Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease Osteoporos Int 7 4 390 406
19. HD Nelson 2002 Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 137 6 529 541
20. DP Trivedi R Doll KT Khaw 2003 Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ 326 7387 469
21. JE Rossouw 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial JAMA 288 3 321 333
22. JA Kanis 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial Bone 33 3 293 300
23. R Marcus 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis J Bone Miner Res 18 1 18 23
24. NB Watts 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk J Clin Endocrinol Metab 88 2 542 549
25. P Dargent-Molina 2002 Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS Prospective Study Osteoporos Int 13 7 593 599
26. WD Leslie 2002 Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk J Clin Densitom 5 2 117 130
27. CW McGrother 2002 Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) Study Osteoporos Int 13 1 89 96
28. C De Laet 2005 Body mass index as a predictor of fracture risk: a meta-analysis Osteoporos Int 16 11 1330 1338
29. O Johnell 2005 Predictive value of BMD for hip and other fractures J Bone Miner Res 20 7 1185 1194
30. JA Kanis 2004 Alcohol intake as a risk factor for fracture Osteoporos Int 16 737 742
31. JA Kanis 2005 A meta-analysis of milk intake and fracture risk: low utility for case finding Osteoporos Int 16 799 804
32. JA Kanis 2004 A family history of fracture and fracture risk: a meta-analysis Bone 35 5 1029 1037
33. JA Kanis 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 6 893 899
34. JA Kanis 2004 A meta-analysis of previous fracture and subsequent fracture risk Bone 35 2 375 382
35. JA Kanis 2005 Smoking and fracture risk: a meta-analysis Osteoporos Int 16 155 162
36. Kanis JA; on behalf of the WSG (2007) Assessment of osteoporosis at a primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield
37. H Johansson 2004 Optimization of BMD measurements to identify high risk groups for treatment-a test analysis J Bone Miner Res 19 6 906 913
38. DC Bauer 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 2 292 299